China Medical System (867) H2 2024 earnings summary

Executive summary

• Turnover declined 6.8% year-over-year to RMB7,469.0 million, mainly due to National Volume Based Procurement (VBP) impacts on three major products.

• Profit for the year dropped 32.3% to RMB1,613.1 million; normalized profit fell 36.7% to RMB1,713.7 million.

• Five innovative drugs (six indications) are now marketed in China, with a robust pipeline of over 40 products and ongoing clinical trials.

• The company is expanding in Southeast Asia, refining its R&D, manufacturing, and commercialization platform.

Financial highlights

• Gross profit decreased 11.2% to RMB5,422.2 million; gross margin fell to 72.6% from 76.2%.

• Selling expenses rose 6.0% to RMB2,661.6 million; administrative expenses increased 18.8% to RMB780.1 million.

• R&D expenditures grew 8.9% to RMB888.3 million, with R&D expenses up 69.1% to RMB330.0 million.

• Net cash from operating activities dropped 49.3% to RMB1,268.5 million.

• Bank balances and cash at year-end were RMB3,706.5 million; bank borrowings reduced to RMB831.3 million.

• Basic EPS decreased 31.9% to RMB0.6673.

• Total dividend per share for the year was RMB0.2681, down 31.6%.

Outlook and guidance

• Focus on innovation-driven growth, specialty breakthroughs, and international expansion, especially in Southeast Asia.

• Plans to enhance operational efficiency through digitalization and AI, and to optimize the international supply chain.

• Continued investment in R&D and commercialization of innovative products to drive future growth.